US Stock MarketDetailed Quotes

BPMC Blueprint Medicines

Watchlist

95.100
+0.470+0.50%

Close Nov 27 16:00 ET

95.100
0.0000.00%

Post 16:02 ET

6.04BMarket Cap-45502P/E (TTM)

Blueprint Medicines Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Blueprint Medicines Q3 2024 Earnings Date

Currency：USDOct 30, 2024

	Estimate (YoY)	Actual (YoY)	Vs Estimate (% Chg)
Revenue	127.47M	128.18M	+717.57K
Beat Est.	+125.34%	+126.61%	+0.56%
EPS	-0.97	-0.89	+0.08
Beat Est.	+55.82%	+59.55%	+8.44%

Analyst Rating

Buy

Nov 27, 2024

Blueprint Medicines Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 10 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual

Estimate

Date	Period	Revenue/Estimate	Earnings Call
--	2025/Q1	-- / 155.955M	--
--	2024/Q4	-- / 145.316M	--
Oct 30, 2024	2024/Q3	128.184M / 127.466M	--
Aug 1, 2024	2024/Q2	138.157M / 103.938M	--
May 2, 2024	2024/Q1	96.116M / 81.445M	--

DatePeriodRevenue/EstimateEarnings Call

--2025/Q1-- / 155.955M--

--2024/Q4-- / 145.316M--

Oct 30, 20242024/Q3128.184M / 127.466M--

Aug 1, 20242024/Q2138.157M / 103.938M--

May 2, 20242024/Q196.116M / 81.445M--

Unlock Free Earnings Estimates

Open Account

Blueprint Medicines Earnings Reports

Blueprint Medicines | 10-Q: Q3 2024 Earnings Report

Oct 30 16:32 ET

Blueprint Medicines | 8-K: Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT® / AYVAKYT ® (avapritinib) Full Year Revenue Guidance

Oct 30 07:11 ET

Blueprint Medicines | 10-Q: Q2 2024 Earnings Report

Aug 1 16:52 ET

Blueprint Medicines | 8-K: Blueprint Medicines Reports Second Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance

Aug 1 07:31 ET